Structured evidence table for Resveratrol Endothelial Function Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Resveratrol Endothelial Function Randomized Trial | Background and aims Menopause is an important cardiovascular risk factor in women likely due to marked estrogen decline. | 2 | Gonçalinho GHF (2026) | The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial. |
| Resveratrol Endothelial Function Randomized Trial | Conclusion Resveratrol increased serum Bcl-2 and cIAP2, and also reduced caspase 9 and circulating EPCs in postmenopausal women with chronic CHD, likely unrelated to circulating SIRT1 and SIRT3. | 2 | Gonçalinho GHF (2026) | The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial. |
| Resveratrol Endothelial Function Randomized Trial | The effects of resveratrol treatment in this population group should be assessed with caution, as a reduction in EPCs is associated with impaired endothelial function and an increased risk of cardiovascular disease. | 2 | Gonçalinho GHF (2026) | The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial. |
| Resveratrol Endothelial Function Randomized Trial | Estrogens affect key processes in atherosclerosis, maintaining endothelial integrity by inhibiting endothelial apoptosis and promoting regeneration through endothelial progenitor cells (EPCs). | 2 | Gonçalinho GHF (2026) | The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial. |
| Resveratrol Endothelial Function Randomized Trial | These abnormalities result from deficient insulin secretion (type 1), resistance to the action of insulin (type 2), or both []. | 3 | Muharib Dina (2026) | Modulatory Effects of Polyphenols on Altered Leukocyte Functions in Thromboinflammation and Diabetes Mellitus |
| Resveratrol Endothelial Function Randomized Trial | The global prevalence of DM has increased dramatically in recent decades, particularly through an increase in type 2 DM (T2DM) driven by a global rise in obesity. | 3 | Muharib Dina (2026) | Modulatory Effects of Polyphenols on Altered Leukocyte Functions in Thromboinflammation and Diabetes Mellitus |
| Resveratrol Endothelial Function Randomized Trial | In addition to traditional cardiovascular risk factors, DM is recognized as a thromboinflammatory condition characterized by dysregulated haemostasis and chronic low-grade inflammation [,]. | 3 | Muharib Dina (2026) | Modulatory Effects of Polyphenols on Altered Leukocyte Functions in Thromboinflammation and Diabetes Mellitus |
| Resveratrol Endothelial Function Randomized Trial | 1 2 3 4 5 Diabetes mellitus (DM) is a group of metabolic disorders characterized by persistent hyperglycaemia defined as a fasting plasma glucose level ≥ 7.0 mmol/L or a random plasma glucose level ≥ 11.1 mmol/L in presence of symptoms or signs of DM or hemoglobin A1c (HbA1c) exceeding 48 mmol/mol []. | 3 | Muharib Dina (2026) | Modulatory Effects of Polyphenols on Altered Leukocyte Functions in Thromboinflammation and Diabetes Mellitus |
Source documents